# A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease

> **NCT07117851** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 20 (estimated)

## Conditions studied

- Extramammary Paget Disease
- Scrotum Disease

## Interventions

- **DRUG:** Disitamab Vedotin combined with Bicalutamide

## Key facts

- **NCT ID:** NCT07117851
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117851, "A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07117851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*